Literature DB >> 12153975

Decreased level of vascular endothelial growth factor in bronchoalveolar lavage fluid of normal smokers and patients with pulmonary fibrosis.

Sekiya Koyama1, Etsuro Sato, Masayuki Haniuda, Hiroki Numanami, Sonoko Nagai, Takateru Izumi.   

Abstract

Vascular endothelial growth factor (VEGF) plays multifunctional roles in both the development of vasculature and the maintenance of vascular function. A decrease in VEGF reduces angiogenesis and induces apoptosis of vascular endothelial cells. Inhibition of the VEGF receptor causes endothelial cell apoptosis and emphysema. We postulated that VEGF concentrations might be reduced in patients with chronic lung diseases. The level of VEGF was evaluated by enzyme-liked immunosorbent assay in bronchoalveolar lavage fluid (BALF) from normal smokers, nonsmoking volunteers, idiopathic pulmonary fibrosis, pulmonary fibrosis associated with a connective tissue disease, and sarcoidosis. The isoforms of VEGF in BALF were determined by high-performance liquid chromatography. VEGF in nonsmoking volunteers was detectable at a high concentration. In contrast, VEGF in most of the normal smokers was below the detectable limit. The VEGF found in nonsmoking volunteers BALF was VEGF165. VEGF was significantly decreased in idiopathic pulmonary fibrosis, pulmonary fibrosis associated with a connective tissue disease, and sarcoidosis compared with nonsmoking volunteers. The smoking patients showed a further decrease in VEGF. These data suggest that the decrease in VEGF in smokers and patients with chronic lung diseases may reduce angiogenesis and induce apoptosis of vascular endothelial cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12153975     DOI: 10.1164/rccm.2103112

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  42 in total

1.  Prostaglandin E2 stimulates the production of vascular endothelial growth factor through the E-prostanoid-2 receptor in cultured human lung fibroblasts.

Authors:  Masanori Nakanishi; Tadashi Sato; Yingji Li; Amy J Nelson; Maha Farid; Joel Michalski; Nobuhiro Kanaji; Xingqi Wang; Hesham Basma; Amol Patil; Jadvinder Goraya; Xiangde Liu; Shinsaku Togo; Myron L Toews; Olaf Holz; Kai-Christian Muller; Helgo Magnussen; Stephen I Rennard
Journal:  Am J Respir Cell Mol Biol       Date:  2012-02       Impact factor: 6.914

Review 2.  Idiopathic Pulmonary Fibrosis: A Genetic Disease That Involves Mucociliary Dysfunction of the Peripheral Airways.

Authors:  Christopher M Evans; Tasha E Fingerlin; Marvin I Schwarz; David Lynch; Jonathan Kurche; Laura Warg; Ivana V Yang; David A Schwartz
Journal:  Physiol Rev       Date:  2016-10       Impact factor: 37.312

Review 3.  Vascular remodelling in the pathogenesis of idiopathic pulmonary fibrosis.

Authors:  S Barratt; A Millar
Journal:  QJM       Date:  2014-01-22

4.  Current Status and Future Opportunities in Lung Precision Medicine Research with a Focus on Biomarkers. An American Thoracic Society/National Heart, Lung, and Blood Institute Research Statement.

Authors:  Ann Chen Wu; James P Kiley; Patricia J Noel; Shashi Amur; Esteban G Burchard; John P Clancy; Joshua Galanter; Maki Inada; Tiffanie K Jones; Jonathan A Kropski; James E Loyd; Lawrence M Nogee; Benjamin A Raby; Angela J Rogers; David A Schwartz; Don D Sin; Avrum Spira; Scott T Weiss; Lisa R Young; Blanca E Himes
Journal:  Am J Respir Crit Care Med       Date:  2018-12-15       Impact factor: 21.405

5.  Vascular endothelial growth factor gene polymorphism and acute respiratory distress syndrome.

Authors:  A R L Medford; L J Keen; J L Bidwell; A B Millar
Journal:  Thorax       Date:  2005-03       Impact factor: 9.139

6.  Involvement of pulmonary endothelial cell injury in the pathogenesis of pulmonary fibrosis: clinical assessment by 123I-MIBG lung scintigraphy.

Authors:  Noriaki Takabatake; Tsuyoshi Arao; Makoto Sata; Shuichi Abe; Sumito Inoue; Yoko Shibata; Yasuchika Takeishi; Isao Kubota
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-09-23       Impact factor: 9.236

7.  Angiogenesis: Future of pharmacological modulation.

Authors:  Manisha Bisht; D C Dhasmana; S S Bist
Journal:  Indian J Pharmacol       Date:  2010-02       Impact factor: 1.200

8.  Different activity of the biological axis VEGF-Flt-1 (fms-like tyrosine kinase 1) and CXC chemokines between pulmonary sarcoidosis and idiopathic pulmonary fibrosis: a bronchoalveolar lavage study.

Authors:  Katerina M Antoniou; Giannoula Soufla; Athanasia Proklou; George Margaritopoulos; Christiana Choulaki; Rena Lymbouridou; Katerina D Samara; Demetrios A Spandidos; Nikolaos M Siafakas
Journal:  Clin Dev Immunol       Date:  2010-02-14

9.  VEGF in the lung: a role for novel isoforms.

Authors:  Julia Varet; Samantha K Douglas; Laura Gilmartin; Andrew R L Medford; David O Bates; Steven J Harper; Ann B Millar
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-03-12       Impact factor: 5.464

10.  Basement membrane and vascular remodelling in smokers and chronic obstructive pulmonary disease: a cross-sectional study.

Authors:  Amir Soltani; David W Reid; Sukhwinder S Sohal; Richard Wood-Baker; Steve Weston; H Konrad Muller; E Haydn Walters
Journal:  Respir Res       Date:  2010-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.